News New data boosts Roche lung cancer combo More positive results from Tecentriq, Avastin and chemo combo
News AbbVie's shares tank after cancer hopeful's phase 2 setback Decision wipes $24 billion from share price
News Roche's Tecentriq halts disease in squamous lung cancer Roche’s cancer immunotherapy Tecentriq has produced strong results which could give it the lead in a key lung cancer indication.
News Merck & Co boosted by Keytruda first-line lung cancer trial KEYNOTE-189 results could see US Merck tighten its grip in cancer immunotherapy.
News Scancell to collaborate with charity CRUK on cancer vaccine Trial will combine cancer vaccine with checkpoint inhibitor
News Roche double trial success could expand use of two new drugs A double trial success from Roche sees it eyeing a combination therapy in lucrative first-line lung cancer, and wider use of its just-approved haemophilia drug, Hemlibra.
News Ipsen' Bylvay fluffs its lines in biliary atresia trial Ipsen's IBAT inhibitor Bylvay has failed a trial in biliary atresia, a rare and serious liver disease that affects babies and has limited treatments.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
